Literature DB >> 21499929

Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma.

Jennifer Rauw1, Shaheeda Ahmed, Teresa Petrella.   

Abstract

Regional Metastatic Melanoma has a relatively high mortality rate. Adjuvant interferon-alpha (IFN-α) has been shown to improve disease-free survival, post-resection. Cardiotoxicity associated with IFN-α use has been described previously in the literature, but here we describe the first case of pericardial effusion with cardiac tamponade secondary to IFN-α 2b treatment of melanoma. Clinicians should be aware of this potentially lethal complication and the possible acuity of its onset.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499929     DOI: 10.1007/s12032-011-9935-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  16 in total

1.  Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha-interferon.

Authors:  H Vacher-Coponat; A Opris; L Daniel; J R Harle; V Veit; M Olmer
Journal:  Nephrol Dial Transplant       Date:  1999-10       Impact factor: 5.992

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

3.  Recombinant alpha 2 interferon-related cardiomyopathy.

Authors:  M C Cohen; M S Huberman; R W Nesto
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

4.  Pericarditis after therapy with interferon-alpha for chronic hepatitis C.

Authors:  A Boonen; R W Stockbrügger; S van der Linden
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

5.  Reversible cardiomyopathy caused by administration of interferon alpha.

Authors:  Aarif Y Khakoo; Marc K Halushka; J Eduardo Rame; E Rene Rodriguez; Edward K Kasper; Daniel P Judge
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-01

6.  Hepatitis C virus-associated pericardial effusion and tamponade in a liver transplant recipient.

Authors:  Lazaros A Nikolaidis; Maher Azzouz; Lois Friedlander; David H Van Thiel; Alan H Gradman
Journal:  Can J Cardiol       Date:  2004-05-15       Impact factor: 5.223

7.  Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy.

Authors:  S Zimmerman; D Adkins; M Graham; P Petruska; C Bowers; D Vrahnos; G Spitzer
Journal:  Cancer Biother       Date:  1994

8.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

9.  Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.

Authors:  Aleksandar Sikole; Pavlina Dzekova; Nexhmi Selja; Magdalena Gaseva; Igor G Nikolov; Mustafa Zabzun; Sheriat Muharemi; Arben Asani; Vili Amitov; Sami Mena; Violeta Grunevska; Ljubomir Ivanovski; Momir Polenakovic
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

10.  Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication.

Authors:  W H Kruit; K J Punt; S H Goey; P H de Mulder; D C van Hoogenhuyze; S C Henzen-Logmans; G Stoter
Journal:  Cancer       Date:  1994-11-15       Impact factor: 6.860

View more
  7 in total

1.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

2.  Interferon-α and pericardial injury: a case report and literature review.

Authors:  Fayaz A Hakim; Sujata Singh; Anil Pandit; Jorge R Alegria; John Camoriano; Melissa L Stanton; Farouk Mookadam
Journal:  Heart Asia       Date:  2014-04-16

Review 3.  Cardiotoxicity of Systemic Melanoma Treatments.

Authors:  Neha Mukunda; Srilakshmi Vallabhaneni; Benedicte Lefebvre; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

Review 4.  Autoimmunity in picornavirus infections.

Authors:  Chandirasegaran Massilamany; Andreas Koenig; Jay Reddy; Sally Huber; Iwona Buskiewicz
Journal:  Curr Opin Virol       Date:  2015-11-08       Impact factor: 7.090

5.  Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma.

Authors:  Farhan Ashraf; Fady Marmoush; Muhammad Ismail Shafi; Ashish Shah
Journal:  Case Rep Cardiol       Date:  2016-06-22

Review 6.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

Review 7.  Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review.

Authors:  Wenxue Zhao; Fanpu Ji; Shanshan Yu; Zongfang Li; Hong Deng
Journal:  Braz J Infect Dis       Date:  2013-10-10       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.